Compare EVO & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | NX |
|---|---|---|
| Founded | 1993 | 1927 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 852.1M |
| IPO Year | N/A | 2008 |
| Metric | EVO | NX |
|---|---|---|
| Price | $2.86 | $17.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $28.00 |
| AVG Volume (30 Days) | 91.4K | ★ 267.3K |
| Earning Date | 04-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,837,641,000.00 |
| Revenue This Year | $1.37 | $4.26 |
| Revenue Next Year | $10.05 | $1.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.81 |
| 52 Week Low | $2.31 | $11.04 |
| 52 Week High | $4.80 | $22.90 |
| Indicator | EVO | NX |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 36.09 |
| Support Level | $2.63 | $16.61 |
| Resistance Level | $3.78 | $20.24 |
| Average True Range (ATR) | 0.09 | 0.82 |
| MACD | -0.04 | -0.41 |
| Stochastic Oscillator | 33.38 | 25.73 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.